Antares Pharma Appoints Jennifer Evans Stacey, Esq., Senior Vice President, General Counsel, Human Resources and Secretary

EWING, N.J.--(BUSINESS WIRE)--

Antares Pharma, Inc. ATRS today announced the appointment of Jennifer Evans Stacey, Esq. to the newly created position of Senior Vice President, General Counsel, Human Resources and Secretary. Jennifer has a diversified corporate background including 20 years of experience in the pharmaceutical industry. Ms. Stacey graduated with a BA from Princeton University and obtained her JD from University of Pennsylvania Law School.

Jennifer comes to Antares Pharma from FXI, Inc. where she served as Senior Vice President, General Counsel, Secretary and Human Resources from November 2012 until May 2014. From January 2005 until February 2012, Ms. Stacey served as Executive Vice President, General Counsel, Human Resources and Secretary at Auxilium Pharmaceuticals, Inc. Prior to that, Ms. Stacey was Senior Vice President, Corporate Communications, and General Counsel of Aventis Behring LLC, a leader in the $6.1 billion global plasma-protein business and a wholly owned subsidiary of Aventis. Prior to the formation of Aventis Behring, Ms. Stacey was with Rhône-Poulenc Rorer (predecessor company of Aventis), first at its headquarters in Collegeville, PA and then at its offices in Paris, France as International Counsel. Ms. Stacey began her legal career at King & Spalding in Washington, DC, where she served as an associate in the Corporate Finance Department.

“We are extremely pleased to welcome Jennifer to the Antares team,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “Jennifer brings a great deal of diversified pharmaceutical experience to the team and will be able to utilize her background in compliance, corporate governance, human resources and corporate strategy in supporting the Company's pursuit of growth and enhanced shareholder value.”

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company has received marketing approval from the U.S. Food and Drug Administration for OTREXUP™ (methotrexate) injection for the treatment of adults with severe active rheumatoid arthritis and children with active polyarticular juvenile idiopathic arthritis. LEO Pharma markets OTREXUP™ to dermatologists for adults with severe recalcitrant psoriasis. Antares Pharma is also developing VIBEX^® QS T for testosterone replacement therapy. The Company's technology platforms include VIBEX^® disposable Medi-Jet, disposable multi-use pen injectors and reusable needle-free injectors marketed as Tjet^® and Zomajet^® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin^® [somatropin (rDNA origin) for injection] human growth hormone (hGH), VIBEX^® epinephrine and several other products. In the U.S. Antares has received FDA approval for Gelnique 3%™ (oxybutynin) gel, a treatment for overactive bladder that is marketed by Actavis. Elestrin^® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Meda Pharma. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company's reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted Medi-Jet and pen injector systems. The Company's corporate office and Product Development and Commercial Groups are located in Ewing, New Jersey.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are indicated by the words “may,” “will,” “plans,” “intends,” “believes,” “expects,” “anticipates,” “potential,” “could,” “would,” “should,” and similar expressions. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, among others, changes in revenue growth and difficulties or delays in the commercial launch of OTREXUP™, market acceptance by physicians and patients of new products, delays in product development and changes or delays in the regulatory process for existing or new product candidates. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2013, and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.